Andrew Scott

2.6k total citations · 1 hit paper
19 papers, 1.1k citations indexed

About

Andrew Scott is a scholar working on Oncology, Molecular Biology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Andrew Scott has authored 19 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 10 papers in Molecular Biology and 7 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Andrew Scott's work include CAR-T cell therapy research (10 papers), Immunotherapy and Immune Responses (5 papers) and Renal and related cancers (4 papers). Andrew Scott is often cited by papers focused on CAR-T cell therapy research (10 papers), Immunotherapy and Immune Responses (5 papers) and Renal and related cancers (4 papers). Andrew Scott collaborates with scholars based in United States, Australia and United Kingdom. Andrew Scott's co-authors include Andrea Schietinger, Mary Philip, Christina S. Leslie, Taha Merghoub, Matthew D. Hellmann, Lauren Fairchild, Mojdeh Shakiba, Jedd D. Wolchok, Peter Lauer and Liping Sun and has published in prestigious journals such as Nature, Journal of Clinical Investigation and Blood.

In The Last Decade

Andrew Scott

19 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Chromatin states define tumour-specific T cell dysfunction and reprogramming

2017 605 citations Mary Philip, Lauren Fairchild et al. Nature profile →

Peers

Countries citing papers authored by Andrew Scott

Since Specialization

Citations

This map shows the geographic impact of Andrew Scott's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew Scott with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew Scott more than expected).

Fields of papers citing papers by Andrew Scott

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew Scott. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew Scott. The network helps show where Andrew Scott may publish in the future.

Co-authorship network of co-authors of Andrew Scott

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew Scott. A scholar is included among the top collaborators of Andrew Scott based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew Scott. Andrew Scott is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work	Indexed citations
1	Ectopic activation of the miR-200c–EpCAM axis enhances antitumor T cell responses in models of adoptive cell therapy 2021 ·Science Translational Medicine ·Minggang Zhang, Zeguo Zhao, Yuri Pritykin, (unknown), Andrew Scott, Fengshen Kuo, Viraj R. Sanghvi, Timothy A. Chan, Venkatraman Seshan, Hans‐Guido Wendel, Andrea Schietinger, Michel Sadelain, Morgan Huse	9
2	Depleting T regulatory cells by targeting intracellular Foxp3 with a TCR mimic antibody 2019 ·OncoImmunology ·Tao Dao, (unknown), Andrew Scott, Casey A. Jarvis, Tatyana Korontsvit, Zhiyuan Yang, Lianxing Liu, Martin G. Klatt, Manuel Guerreiro, Annamalai Selvakumar, Elliott J. Brea, Claire Y. Oh, Liu C, David A. Scheinberg	21
3	ACTR-55. TUMOR VOLUME AS A PREDICTOR OF RESPONSE TO ANTI-EGFR ADC ABT-414 2018 ·Neuro-Oncology ·Hui Gan, (unknown), Eddie Lau, Sze-Ting Lee, Malaka Ameratunga, (unknown), Diana Cao, Angela Rigopoulos, Ho‐Jin Lee, Erica Gomez, David Maag, Andrew Scott	2
4	A therapeutic T cell receptor mimic antibody targets tumor-associated PRAME peptide/HLA-I antigens 2017 ·Journal of Clinical Investigation ·Aaron Y. Chang, Tao Dao, Ron S. Gejman, Casey A. Jarvis, Andrew Scott, Leonid Dubrovsky, Melissa Mathias, Tatyana Korontsvit, Victoriya Zakhaleva, Michael Curcio, Ronald C. Hendrickson, Liu C, David A. Scheinberg	68
5	Chromatin states define tumour-specific T cell dysfunction and reprogramming breakdown → 2017 ·Nature ·Mary Philip, Lauren Fairchild, Liping Sun, (unknown), (unknown), Mojdeh Shakiba, Andrew Scott, Agnès Viale, Peter Lauer, Taha Merghoub, Matthew D. Hellmann, Jedd D. Wolchok, Christina S. Leslie, Andrea Schietinger	605
6	EXTH-56. EGFR EXTRACELLULAR DOMAIN POINT MUTANT A289V: A THERAPEUTICALLY TARGETABLE DRIVER OF GLIOBLASTOMA INVASION 2017 ·Neuro-Oncology ·Amy Haseley Thorne, Zev A. Binder, Spyridon Bakas, E. Paul Wileyto, Jennifer J.D. Morrissette, Hamed Akbari, Saima Rathore, Andrew Scott, Christos Davatzikos, Donald M. O’Rourke, Frank B. Furnari	1
7	Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1 2015 ·Nature Biotechnology ·Tao Dao, Dmitry Pankov, Andrew Scott, Tatyana Korontsvit, Victoriya Zakhaleva, Yiyang Xu, Jingyi Xiang, Su Yan, Manuel Guerreiro, Nicholas Veomett, Leonid Dubrovsky, Michael Curcio, Ekaterina Doubrovina, Vladimir Ponomarev, Liu C, Richard J. O’Reilly, David A. Scheinberg	126
8	A Therapeutic TCR Mimic Monoclonal Antibody for Intracellular PRAME Protein in Leukemias 2015 ·Blood ·Aaron Y. Chang, Tao Dao, Andrew Scott, Leonid Dubrovsky, Liu C, David A. Scheinberg	6
9	Wilms´Tumor 1 Protein Is Highly Expressed on Malignant Plasma Cells and Provides a Novel Target for Immunotherapeutic Approaches 2015 ·Blood ·Guenther Koehne, Satyajit Kosuri, Ekaterina Doubrovina, Tao Dao, Andrew Scott, Achim A. Jungbluth, Richard J. O’Reilly	1
10	A TCR-mimic antibody to WT1 bypasses tyrosine kinase inhibitor resistance in human BCR-ABL+ leukemias 2014 ·Blood ·Leonid Dubrovsky, Dmitry Pankov, Elliott J. Brea, Tao Dao, Andrew Scott, Su Yan, Richard J. O’Reilly, Liu C, David A. Scheinberg	41
11	Targeting the Intracellular WT1 Oncogene Product with a Therapeutic Human Antibody 2013 ·Science Translational Medicine ·Tao Dao, Su Yan, Nicholas Veomett, Dmitry Pankov, (unknown), Tatyana Korontsvit, Andrew Scott, (unknown), P. Maslak, Emily Casey, (unknown), Hong Liu, Victoria Zakhaleva, Michael Curcio, Ekaterina Doubrovina, Richard J. O’Reilly, Liu C, David A. Scheinberg	136
12	A Bi-Specific T Cell Engaging Monoclonal Antibody (mAb) Derived From a TCR-Like Mab Specific For WT1/HLA-A0201 (ESK-BiTE) Shows a Potent Activity Against Human AML and Ph+ ALL In Mouse Models 2013 ·Blood ·Dmitry Pankov, Tao Dao, (unknown), Andrew Scott, Tatyana Korontsvit, Victoria Zakhaleva, Nicholas Veomett, Michael Curcio, Ekaterina Doubrovina, Richard J. O’Reilly, (unknown), David A. Scheinberg	2
13	Mechanisms of resistance to high and low linear energy transfer radiation in myeloid leukemia cells 2012 ·Blood ·(unknown), Andrew Scott, David A. Scheinberg	24
14	Immunotherapy of melanoma: Targeting defined antigens 1997 ·Australasian Journal of Dermatology ·Jonathan Cebon, Duncan MacGregor, Andrew Scott, R. J. deBoer	8
15	Current status of radioimmunodetection 1994 ·Nuclear Medicine and Biology ·Steven M. Larson, Chaitanya Divgi, Andrew Scott, Farhad Daghighian, Homer A. Macapinlac, Sydney Welt	1
16	Current status of radioimmunotherapy 1994 ·Nuclear Medicine and Biology ·Steven M. Larson, Chaitanya Divgi, Andrew Scott, George Sgouros, Martin C. Graham, Lale Kostakoglu, David A. Scheinberg, Nai‐Kong V. Cheung, Jeffrey Schlom, Ronald D. Finn	14
17	Studies of enzyme-mediated reactions. Part 161. Stereochemical course of the formation of 5-hydroxytryptamine (serotonin) by decarboxylation of (2)-5-hydroxytryptophan with the aromatic L-amino acid decarboxylase (E.C. 4.1.1.28) from hog kidney 1990 ·Tetrahedron ·(unknown), Andrew Scott, James Staunton	4
18	Reiteration frequency of the gene for tissue-specific histone H5 in the chicken genome 1976 ·Nature ·Andrew Scott, J. R. E. Wells	14
19	The isolation of chicken histone F2c (V) messenger RNA by immunoadsorption of F2c-synthesising polysomes 1975 ·Biochemical and Biophysical Research Communications ·Andrew Scott, J. R. E. Wells	14

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact